文献速递特殊人群用药药物不良反应与药物警戒

日本妊娠药物信息研究所咨询病例数据库的数据质量与效用评估

Evaluation of Data Quality and Utility of the Japan Drug Information Institute in Pregnancy (JDIIP) Consultation Case Database for Pregnancy Pharmacovigilance.
PubMed 文献 · Drug Saf · 2025-05-15

本研究以欧盟ConcePTION项目提出的48项妊娠药物警戒核心数据元素为参照,评估日本妊娠药物信息研究所(JDIIP)数据库的质量与效用。结果显示,JDIIP可直接收集或可推导出48项中的38项(79%),在数据库管理、妊娠详情、母亲病史、妊娠药物暴露、活产/死产结局及畸形详情等类别覆盖超过80%,但妊娠期新发母亲疾病和婴儿1岁内并发症等类别覆盖低于50%。

要点

  • JDIIP数据库覆盖ConcePTION项目48项核心数据元素中的38项(79%)。
  • 数据库管理、妊娠详情、母亲病史、药物暴露、出生结局及畸形详情等类别覆盖超80%。
  • 妊娠期新发母亲疾病和婴儿1岁内并发症等类别覆盖低于50%,需加强收集。

核心结论

  • JDIIP数据库与ConcePTION核心数据元素框架高度对齐,是推进日本妊娠药物警戒研究的有价值资源。
  • 部分母亲与婴儿数据元素的收集有待改进,以进一步增强药物警戒能力。

研究设计与样本

  • 研究将JDIIP数据库与欧盟ConcePTION项目提出的48项妊娠药物警戒核心数据元素(CDEs)进行详细映射比对。
  • 比对涵盖母亲生活方式因素、药物暴露和妊娠结局等CDE定义与JDIIP对应数据元素。

主要发现

  • JDIIP数据库可直接收集或可推导出48项推荐CDEs中的38项(79%)。
  • 数据库管理详情、妊娠详情、母亲病史、妊娠药物暴露、活产/死产出生结局及畸形详情等类别覆盖超过80%的必要变量。
  • 妊娠期新发母亲疾病和婴儿1岁内并发症等类别覆盖低于50%。

关键数值与推荐

  • ConcePTION项目提出48项妊娠药物警戒核心数据元素(CDEs)。
  • JDIIP对48项CDEs的覆盖率为79%(38/48)。
  • 部分类别覆盖率超过80%,部分类别低于50%。

临床怎么用

  • 可将JDIIP数据库作为日本妊娠药物警戒的数据资源,用于整合和利用妊娠期药物暴露数据。
  • 针对覆盖率低于50%的类别(如妊娠期新发母亲疾病、婴儿1岁内并发症),可优化数据收集以提升与CDE框架的对齐度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Ensuring medication safety during pregnancy is crucial for protecting maternal and fetal health. However, fragmented data sources and the lack of comprehensive databases present substantial barriers to effective pharmacovigilance. The Japan Drug Information Institute in Pregnancy (JDIIP) database, which contains data on drug treatment counseling for pregnant women, is expected to help address the lack of comprehensive databases for pregnancy pharmacovigilance (PregPV). OBJECTIVE: We evaluated the quality and utility of the JDIIP database for PregPV activities, particularly its ability to consolidate and utilize drug-exposure data among pregnant women in Japan. METHODS: To assess the quality and utility of the JDIIP database for PregPV, we examined its alignment with 48 core data elements (CDEs) considered critical for PregPV, as recently proposed by a European Union consortium through the ConcePTION Project. We performed a detailed mapping of each CDE definition-including maternal lifestyle factors, drug exposure, and pregnancy outcomes-against the corresponding data elements captured in the JDIIP database. RESULTS: The JDIIP database either directly collected or could derive 38 of the 48 specific items (79%) recommended by the ConcePTION Project. At the category level, the JDIIP database aligned closely with the CDE requirements for database management details, pregnancy details, maternal medical history, pregnancy medication exposure, live/stillborn birth outcomes, and malformation details, achieving coverage of over 80% of the necessary variables in each category. Some categories, such as maternal medical conditions arising during pregnancy and infant complications within the first year of life, showed less alignment, with coverage rates below 50%. Although the JDIIP database provides comprehensive coverage of critical pharmacovigilance elements, data collection for specific variables and categories that better align with the CDE framework can be enhanced to improve alignment with the CDE framework and strengthen pharmacovigilance capabilities. CONCLUSIONS: Our findings highlight the potential of the JDIIP database as a valuable resource for advancing PregPV research. Although the collection of certain maternal and infant data elements could be improved, the substantial alignment of the database with established CDEs positions it as a promising tool for advancing PregPV initiatives in Japan.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Matsuda S, Yakuwa N, Goto M, et al. Evaluation of Data Quality and Utility of the Japan Drug Information Institute in Pregnancy (JDIIP) Consultation Case Database for Pregnancy Pharmacovigilance. Drug Saf. 2025. PMID: 40374964. doi:10.1007/s40264-025-01554-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。